Primary vulvar Paget disease - the importance of clinical suspicion by Mota, F. et al.
UC Davis
Dermatology Online Journal
Title
Primary vulvar Paget disease – the importance of clinical suspicion
Permalink
https://escholarship.org/uc/item/6ff381x4
Journal
Dermatology Online Journal, 23(10)
Authors
Mota, Fernando
Horta, Miguel
Marques, Claudia
et al.
Publication Date
2017-01-01
License
CC BY-NC-ND 4.0
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Volume 23 Number 10 | October 2017 
DOJ 23 (10): 10
- 1 - 
Dermatology Online Journal  ||  Case Presentation
Fernando Mota1, Miguel Horta1, Claudia Marques2, Susan Foreid3, Manuela Selores1,4,5
Affiliations: 1Dermatology Department, Centro Hospitalar do Porto, Portugal, 2Ginecology and Obstetrics Department, Centro 
Hospitalar do Porto, Portugal, 3Anatomo-pathology, Laboratório Macedo Dias, Porto, Portugal, 4Dermatology Research Unit, Centro 
Hospitalar do Porto, Portugal, 5Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Portugal
Corresponding Author: Fernando Mota, Rua Central, 180, Branzelo, 4515-498 Melres, Portugal, Email: fernandojrmota@gmail.com
Primary vulvar Paget disease – the importance of clinical 
suspicion
Keywords: extramammary Paget disease; vulvar Paget 
disease; vulvar oncology
Introduction
Vulvar cancer is the fourth most common gynecologic 
cancer comprising five percent of malignancies 
involving the female genital tract. Extramammary 
Paget disease (EMPD) of the vulva is a rare disease 
that accounts for only 1-2% of vulvar malignancies 
and represents a frequent cause of misdiagnosis [1,2]. 
We present a case of primary vulvar EMPD treated 
with simple vulvectomy.
Case Synopsis
A 78-year-old woman was referred to our department 
owing to a 3-year history of a pruritic cutaneous 
plaque with an eczematous appearance located 
in the suprapubic area and extending to the vulva. 
She had undergone previous treatments with 
topical corticosteroids, alone and in association 
with vitamin D derivatives and antifungals, without 
improvement. Her past medical history was 
otherwise unremarkable. There was no family history 
of skin disease. Age appropriate cancer screening 
was up-to-date and without changes. On physical 
examination, the patient had an erythematous, well-
demarcated plaque with scaling and ulcerated areas 
occupying the suprapubic area and labia majora 
(Figure 1). No other relevant changes were found, 
including adenopathies or organomegalies.
Owing to a clinical suspicion of Paget disease, a 
skin biopsy was performed revealing an epidermal 
infiltrate composed of aggregates of large atypical 
cells with vesicular nuclei, prominent nucleoli, and 
clear cytoplasm; mitoses were also visible (Figure 
2a, b). Immunostaining was positive for cytokeratin 
(CK) 7, carcinoembryonic antigen (CEA), and human 
epidermal growth factor receptor (HER) 2 (Figure 
2c-e). Stains were negative for cytokeratin (CK) 20, 
Abstract
Extramammary Paget disease of the vulva is a rare 
condition that accounts for only 1-2% of vulvar 
malignancies and represents a frequent cause 
of misdiagnosis. It is most commonly seen in 
postmenopausal women. Clinically it is similar to 
Paget disease of the breast, appearing as red, well-
demarcated eczematoid lesions, with slightly raised 
edges. A high degree of clinical suspicion is very 
important when evaluating these lesions in order to 
avoid misdiagnosis and delay of effective treatment. 
We present a case of vulvar Paget disease treated with 
vulvectomy.
Figure 1. Clinical aspect of the lesion.
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MelanA, and p63 (Figure 2f-h) , and S100 protein 
(not shown).
A thoracoabdominopelvic computed tomography 
and a colonoscopy were performed and did not 
reveal an underlying neoplasm. A diagnosis of 
primary vulvar EMPD was made. After discussing 
treatment options with the patient, she was referred 
to the gynecology department for treatment and a 
simple vulvectomy was performed (Figures 3, 4). 
She has remained disease-free after a follow-up of 16 
months.
Case Discussion
Extramammary Paget disease was first 
described in 1889 by Crocker, whereas 
Dubreuilh reported the first case of Paget 
disease of the vulva in 1901 [3,4]. It is a rare 
intra-epithelial adenocarcinoma, which 
affects mainly postmenopausal women [5]. 
Most patients are Caucasian and in their 
60s or 70s [6-8].
The vulva is the most common site of 
extra-mammary PD [9]. Other affected 
body regions include: perianal region, 
groin, thigh, buttocks, axilla, eyelids, and 
external ear canal [9]. Scrotum and penis 
involvement may also be found in men [9].
EMPD may be primary or secondary [9,10]. 
Primary EMPD accounts for the majority of 
cases and is believed to arise from cutaneous 
adnexal glandular epithelium; it is not 
associated with underlying malignancies. 
The cell origin of primary PD is uncertain 
[9]. The Paget cells in secondary EMPD are 
thought to be epidermotropic metastatic 
cancer cells from a visceral adenocarcinoma 
[9,10].
Clinically, EMPD typically presents as a well-
demarcated red or brown plaque with an 
eczematoid appearance, with variable areas 
of induration, crusting, scaling, or ulceration 
[11]. Pruritus is a common complaint [5].
EMPD is a frequent cause of misdiagnosis 
and thus delayed effective treatment. It 
has been reported that the time from onset 
of symptoms to diagnosis can range up to over 30 
years [9]. Clinical differential diagnoses may include 
cutaneous candidiasis, tinea cruris, seborrheic 
dermatitis, psoriasis, Bowen disease, or melanoma 
(pigmented variant of EMPD).
Histology is required to confirm the diagnosis and 
immunohistopathology helps to distinguish this 
disease from other entities such as atypical squamous 
cell carcinoma and melanoma [12,13]. Typical 
histological findings are large cells (Paget cells) with 
abundant basophilic, finely granular cytoplasm and 
Figure 2. Histology and immunohistochemistry: a) H&E, 4%; b) H&E, 10%; Im-
munohistochemistry, 10%, positivity for c) CK7, d) CEA and e) HER2. Immunohis-
tochemistry, 10%, negative for f )-h) CK20, MelanA and p63, respectively.
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a large central nucleus, sometimes with a prominent 
nucleolus [12]. Pronounced nuclear atypia and 
pleomorphism are present. These cells might be 
found isolated or in clusters. Most cells are found 
in the lower epidermis, although infiltration of the 
upper strata may also be seen [12]. The combination 
of careful observation of morphological features 
with appropriate histochemical stains (positivity for 
Cam 5.2, Epithelial Membrane Antigen, CEA) allows 
confirmation of the diagnosis in most cases in clinical 
practice [12,13]. In our case, the combination of 
positive CK 7 and CEA and negative p63 was used to 
distinguish EMPD from in situ ‘pagetoid’ squamous 
cell carcinoma. The negativity for MelanA and S100 
protein excluded melanocytic differentiation, namely 
melanoma. CK 20 is typically positive in pagetoid 
spread of underlying regional internal malignancy. 
The combination of positive CK 7 and negative CK 
20 was useful in distinguishing primary EMPD from 
a pagetoid spread of extracutaneous malignancies.
It has been established that vulvar EMPD has a 
positive association with other internal malignancies, 
with a frequency of around 20% [5,8]. Particularly, 
it has been reported to be associated with an 
underlying adnexal carcinoma in 4-17% of cases 
[8]. Furthermore, different sites of EMPD may be 
associated with different underlying tumors [12]. 
EMPD of the external male and female genitalia may 
be associated with neoplasms arising in the bladder 
and urethra, and in the prostate in men [12]. EMPD of 
the perianal skin is often associated with colorectal 
tumors [12]. Some cases have been reported to 
involve the skin of the extremities and abdomen [12].
Although there is no consensus about which tests 
should be performed, the diagnosis of EMPD should 
prompt a comprehensive age-appropriate cancer 
screening (including colonoscopy, urinalysis, Pap 
smear and mammography in women, prostate-
specific antigen measurement in men), [14]. The 
authors consider that an abdominal and pelvic 
ultrasonography or computed tomography can 
be further performed to exclude urinary tract 
involvement. Early diagnosis and long-term follow-
up are the keys to successful management.
The standard treatment is local excision of the affected 
area with adequate margins. However, 40~45% of 
cases recur after surgery within 4 years [15]. Other 
treatments for localized, inoperable, or recurrent 
disease include photodynamic therapy, laser 
therapy, radiotherapy, topical treatments, or even 
chemotherapy [16-18]. Among topical treatments, 
imiquimod has shown good response rates (71% of 
complete response), [19]. With close follow-up, it may 
be used in women with EMPD of the vulva to avoid 
surgery. It may also be used in cases with involved 
surgical resection margins, given that the patient is 
willing to tolerate local side effects [19].
The prognosis varies according to the degree 
of invasion and the presence of an underlying 
carcinoma (excellent in EMPD confined to the 
epidermis compared to 0% 5-year survival in the 
Figure 3. Intra-operative aspect of simple vulvectomy.
Figure 4. Immediate post-operative aspect after simple 
vulvectomy with complete clearance of the lesion.
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presence of inguinal lymph node metastases), [12]. 
Lengthy follow up is advocated for all cases of EMPD. 
In our case only the vulva was involved and complete 
clearing of the tumor was achieved with surgical 
excision.
Conclusion
The authors present a case of a disease in which a 
high degree of clinical suspicion is very important 
in order to avoid misdiagnosis and delay in effective 
treatment.
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